Evotec

AEOVIAN PHARMACEUTICALS DOSES FIRST PARTICIPANTS IN PHASE 1 CLINICAL TRIAL, STRENGTHENS LEADERSHIP TEAM AND RAISES ADDITIONAL $50 MILLION FINANCING

Retrieved on: 
Thursday, March 28, 2024
Xenon, TSC, Epilepsy, Alexion Pharmaceuticals, Patient, Sale, Investment, Therapy, Melinda French Gates, Jazz Pharmaceuticals, Genetic disorder, Ageing, CIO, Notifiable disease, Biotechnology, Yale University, CNS, NIH, Zajac, University of Bristol, Honours degree, UCSF, Drug discovery, Evotec, GW Pharmaceuticals, Genetic distance, DSM-IV codes, Wesleyan University, Growth, CFO, BIO, Record, Bachelor of Science, Morgan Stanley, Former, Pharmaceutical industry

BERKELEY, Calif., March 28, 2024 /PRNewswire/ -- Aeovian Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel and highly selective therapeutics that potently inhibit the mTORC1 pathway, today announced that it has dosed the first cohort of participants in a Phase 1 clinical trial for its lead development candidate AV078, a first-in-class CNS penetrant selective mTORC1 inhibitor. Supporting this transition into the clinic, the company has also expanded its leadership team with the appointment of seasoned industry veterans William Greene, M.D., Chief Investment Officer at Hevolution, and Justin Gover, former Chief Executive Officer of GW Pharmaceuticals, to the company's Board of Directors, and appointed Micah Zajic as Chief Financial Officer. The company also recently completed a $50 million financing, led by Hevolution.

Key Points: 
  • Aeovian has assembled a compelling platform for the development of selective mTORC1 inhibitors," said Dr. Greene, CIO at Hevolution.
  • In the $50M financing, Hevolution was joined by existing investors Apollo Health Ventures, Sofinnova Investments, venBio, Evotec and b2venture.
  • This financing will support the completion of the Phase 1 clinical trial in healthy volunteers and prepare for the start of a subsequent Phase 2 clinical trial in adult and pediatric patients with TSC refractory epilepsy.
  • As CEO, he built and led Iconic Therapeutics through discovery, clinical development, and venture financing, which culminated in a successful sale of the company.

Domain Therapeutics Promotes Stephan Schann as Chief Scientific Officer (CSO)

Retrieved on: 
Tuesday, February 27, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, PAR2, Multimedia, G protein-coupled receptor, Growth, Medicinal chemistry, Evotec, University, Therapy, GPCR, Gq alpha subunit, Biomedical Research, Patient, Intellectual property, Knowledge, CSO, Cancer

Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the expansion of the Company’s executive management team with the appointment of Stephan Schann as Chief Scientific Officer (CSO).

Key Points: 
  • Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the expansion of the Company’s executive management team with the appointment of Stephan Schann as Chief Scientific Officer (CSO).
  • Stephan will oversee the development of Domain’s proprietary pipeline and its highly innovative R&D center based in Strasbourg, France.
  • Stephan has also contributed significantly to the Company’s scientific achievements and strategic direction.
  • Dr. Tony Johnson, President and Chief Executive Officer of Domain Therapeutics, said: “We are thrilled to have Stephan be promoted into the role of Chief Scientific Officer.

EQS-News: Evotec-partner Jingxin receives approval for EVT201 in China

Retrieved on: 
Thursday, December 14, 2023
Frankfurt Stock Exchange, ALL, MDAX, Incidence, EVT201, EVO, GABAA, Woman, Partnership, LTD, ISIN, KOREA, Pharmaceutical industry, Insomnia, Evotec

EVOTEC’S LICENCE PARTNER ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD (“JINGXIN”) WILL LEAD ALL COMMERCIALISATION EFFORTS FOR EVT201 IN CHINA AND SOUTH KOREA

Key Points: 
  • EVOTEC’S LICENCE PARTNER ZHEJIANG JINGXIN PHARMACEUTICAL CO., LTD (“JINGXIN”) WILL LEAD ALL COMMERCIALISATION EFFORTS FOR EVT201 IN CHINA AND SOUTH KOREA
    Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that Zhejiang Jingxin Pharmaceutical Co., Ltd (“Jingxin”) has received the approval from the Chinese National Medical Products Administration (“NMPA”) for the novel insomnia treatment EVT201, also known as Dimdazenil in China.
  • The Company led clinical Phase II development for EVT201, yielding positive safety and efficacy results, before licensing the programme out to Jingxin for further development and commercialisation in China.
  • Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “We are excited to see Jingxin announce the approval of EVT201 as a novel short-term treatment of insomnia.
  • We have full confidence in our partner Jingxin for the commercialisation of EVT201 in China and South Korea to respond to the unmet medical need of insomnia patients.”

EQS-News: Evotec enters partnership with Charité to expand molecular patient database in autoimmune diseases

Retrieved on: 
Thursday, December 14, 2023
EVO, B cell, Proteomics, Anti-neutrophil cytoplasmic antibody, Disease, Research, Inflammation, Partnership, Metabolomics, ISIN, AAV, Patient, Genomics, MDAX, Collection, ANCA, Database, Nephrology, Principal, Frankfurt Stock Exchange, Therapy, Blood, Pharmaceutical industry, Medical imaging, Evotec

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered a partnership with Charité Universitätsmedizin Berlin (“Charité”), one of the leading and largest university hospitals in Europe, to generate a molecular patient database for ANCA-associated vasculitis (“AAV”), a collection of relatively rare autoimmune diseases of unknown cause, characterised by inflammation of blood vessels.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered a partnership with Charité Universitätsmedizin Berlin (“Charité”), one of the leading and largest university hospitals in Europe, to generate a molecular patient database for ANCA-associated vasculitis (“AAV”), a collection of relatively rare autoimmune diseases of unknown cause, characterised by inflammation of blood vessels.
  • The strategic partnership between Evotec and Charité aims at achieving a better disease understanding of AAV by creating a unique longitudinal PanOmics database from the analysis of patient material.
  • Together with supplementary pseudonymised patient data, these PanOmics data will feed into Evotec’s proprietary translational molecular patient data platform E.MPD, which serves as the central data repository for molecular patient data.
  • Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: “We are delighted to announce this exciting new partnership with Charité, a renowned centre of medical excellence in Germany, and expand Evotec’s E.MPD database within autoimmune diseases.

EQS-News: Evotec SE reports results for the first nine months 2023 and provides corporate update

Retrieved on: 
Thursday, December 14, 2023
Growth, Bridge, Drug discovery, Evotec, EVO, Novo Nordisk, Mass General Brigham, Biomarker, ISIN, Research, Frankfurt Stock Exchange, MDAX, Creative Biolabs, Yale University, Harvard University, EBITDA, MBC, Match point, LabCentral, Pharmaceutical industry, Arms industry, Fine chemical, Silviculture

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the financial results and corporate updates for the first nine months 2023.

Key Points: 
  • Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced the financial results and corporate updates for the first nine months 2023.
  • Costs of € 43.9 m were incurred in 2023 as a direct result of the cyber-incident in early April, including additional external expenditures and internal recovery contributions.
  • In response to the criminal cyber-attack, Evotec took immediate action to contain and remediate the attack by taking its external-facing systems offline.
  • This was deemed necessary to protect all the Company’s partners and stakeholders and meant Evotec could ensure that the integrity of scientific data remained unaffected.

Dewpoint Therapeutics Enters Strategic Partnership with Evotec to Accelerate Oncology Pipeline

Retrieved on: 
Tuesday, November 7, 2023
MDAX, Frankfurt Stock Exchange, IND, Therapy, ISIN, EVO, Risk, Partnership, Hotel des Indes (The Hague), Dew point, IndiGo, AI, Sales, Pharmaceutical industry, Evotec

Under the collaboration, Evotec will facilitate the rapid development of Dewpoint’s oncology assets using Evotec’s fully integrated clinical-enabling INDiGO platform to de-risk and accelerate the path to clinical testing.

Key Points: 
  • Under the collaboration, Evotec will facilitate the rapid development of Dewpoint’s oncology assets using Evotec’s fully integrated clinical-enabling INDiGO platform to de-risk and accelerate the path to clinical testing.
  • Dr. Matthias Evers, Chief Business Officer of Evotec, commented, “We are excited to enter this strategic development partnership with Dewpoint.
  • By combining our complementary expertise, Evotec’s development platform will serve as the capital-efficient IND engine for this highly collaborative partnership.
  • We look forward to working closely together with their team to make Dewpoint’s groundbreaking innovations available to patients.”
    “Dewpoint’s strategic partnership with Evotec leverages the world-class speed of their development platform to accelerate our oncology assets into the clinic.

EQS-News: Evotec and Dewpoint Therapeutics enter strategic partnership in oncology

Retrieved on: 
Tuesday, November 7, 2023
MDAX, IND, Therapy, ISIN, Frankfurt Stock Exchange, INDIGO, EVO, Risk, Partnership, A.I, Hotel des Indes (The Hague), Dew point, IndiGo, Sales, Pharmaceutical industry, Evotec

The partnership brings together Dewpoint’s advanced oncology pipeline programmes discovered using its groundbreaking condensate biology and A.I.

Key Points: 
  • The partnership brings together Dewpoint’s advanced oncology pipeline programmes discovered using its groundbreaking condensate biology and A.I.
  • Dr Matthias Evers, Chief Business Officer of Evotec, commented: “We are excited to enter this strategic development partnership with Dewpoint.
  • By combining our complementary expertise, Evotec’s development platform will serve as the capital-efficient IND engine for this highly collaborative partnership.
  • We look forward to working closely together with their team to make Dewpoint’s groundbreaking innovations available to patients.”
    “Dewpoint’s strategic partnership with Evotec leverages the world-class speed of their development platform to accelerate our oncology assets into the clinic.

Prokarium Achieves Major Milestone with FDA's IND Approval for Bladder Cancer Program

Retrieved on: 
Thursday, November 2, 2023
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Vanderbilt-Ingram Cancer Center, Achilles, IND, Food, Evotec, MD, Bladder cancer, GSK plc, Doctor of Philosophy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Albright, Doctor of Pharmacy, Recurrence, Immunotherapy, Therapy, BCG, Synthetic biology, Patient, Cancer, Investigational New Drug, Pharmaceutical industry

Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create novel cancer treatments, today announces that the U.S. Food and Drug Administration (FDA) has granted the company's Investigational New Drug (IND) application for their immunotherapy ZH9.

Key Points: 
  • Prokarium, a biopharmaceutical company at the forefront of applying synthetic biology to create novel cancer treatments, today announces that the U.S. Food and Drug Administration (FDA) has granted the company's Investigational New Drug (IND) application for their immunotherapy ZH9.
  • The approval enables initiation of the clinical development program for ZH9 in the U.S., focusing on patients with non-muscle invasive bladder cancer.
  • "The FDA’s approval of our IND application is an important milestone and a clear recognition of the preclinical data already generated for ZH9,” stated Prokarium’s CEO, Kristen Albright, PharmD.
  • Dara brings over two decades of experience in biotech and large pharma.

EQS-News: Evotec, ClavystBio, Leaps by Bayer, Lightstone Ventures and Polaris Partners launch '65LAB'

Retrieved on: 
Tuesday, October 17, 2023
Partnership, NUS, National university, Drug development, MDAX, Polaris Partners, SCIENCE, Duke–NUS Medical School, Therapy, RESEARCH, National University of Singapore, FOR, Agency for Science, Technology and Research, Patient, Bayer, EVO, Frankfurt Stock Exchange, Academic Partnerships, SE, Growth, Evotec, Public sector, Duke University, University, LEAPS, POLARIS, Drug discovery, ISIN, Agency, AND, Pharmaceutical industry, Research, Science

“65LAB”, Evotec’s first academic BRIDGE in Asia, aims to advance drug discovery and the creation of new therapeutics companies in Singapore.

Key Points: 
  • “65LAB”, Evotec’s first academic BRIDGE in Asia, aims to advance drug discovery and the creation of new therapeutics companies in Singapore.
  • 65LAB was founded to establish a model of long-term partnership to foster future company growth and the development of Singapore’s biotech ecosystem.
  • 65LAB selects promising academic projects and invests up to US$ 1.5 m in each project over the course of 18-24 months.
  • The Board provides oversight and governance to 65LAB’s strategy and operations and includes Dr Wen Qi Ho, Therapeutics Lead, ClavystBio, Dr Christina Isacson, Partner, Lightstone Ventures, Dr Pei Sze Ng, Director, Leaps by Bayer, and Dr Kim Png, Principal, Polaris Partners.

The Multiple Myeloma Research Foundation (MMRF) Names Stephanie Oestreich, Ph.D., MPA, as Managing Director of the Myeloma Investment Fund (MIF)

Retrieved on: 
Thursday, October 5, 2023
Biotechnology, Health, Other Health, Pharmaceutical, Other Philanthropy, Philanthropy, Oncology, Other Science, Research, General Health, Fund Raising, Health Technology, Foundation, Science, RA, John F. Kennedy High School, Faculty, Business, Drug development, ARCH Venture Partners, Multiple myeloma, Multiple Myeloma Research Foundation, Harvard University, Novartis, American Business Council Nigeria, Arm, Galecto Biotech, Therapy, W20, MMRF, MIT, G20, MPA, Growth, CART, Evotec, Business development, Commercial, Patient, Management, Bruker

The Multiple Myeloma Research Foundation (MMRF) has announced the appointment of Stephanie Oestreich, Ph.D., MPA, as Managing Director of its venture philanthropy subsidiary, the Myeloma Investment Fund (MIF).

Key Points: 
  • The Multiple Myeloma Research Foundation (MMRF) has announced the appointment of Stephanie Oestreich, Ph.D., MPA, as Managing Director of its venture philanthropy subsidiary, the Myeloma Investment Fund (MIF).
  • In this role, Dr. Oestreich will lead the overall execution of the MIF’s investment strategy and serve as a member of the MMRF executive leadership team.
  • “We are thrilled to have Dr. Oestreich join our team as Managing Director of the MIF,” said Michael Andreini, President and CEO, the MMRF.
  • “The MIF invests in the most promising companies that are developing innovative clinical assets and technologies that could be transformative for myeloma patients.